Genenta Science S.p.A. stock surged after ANEMOCYTE partnership. Discover temferon's cancer trial updates and what’s next.

Genenta & Anemocyte ink partnership to advance off-the-shelf LVV Plasmid DNA production: Milan Monday, October 27, 2025, 14:00 Hrs [IST] Genenta Science, a pioneer company in immu ...

Genenta Science shares surged by more than double Friday after the company said it has partnered with Anemocyte to collaborate on its plasmid DNA technology platform. The stock was briefly halted from ...

Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today announced a strategic collaboration with ...

Investing.com -- Genenta Science (NASDAQ:GNTA) stock soared 241.8% in premarket trading Friday after announcing a strategic collaboration with ANEMOCYTE focused on off-the-shelf lentiviral vector ...

Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today ...

The Company treated the first patient in the pivotal Phase 3 OVATION 3 Study in July 2025 and is working with trial investigators to expand clinical sites and accelerate enrollment. Four sites have ...

Genenta Science shares surged 300% in premarket trading on Friday after announcing an expanded collaboration with ANEMOCYTE.

An increasing demand for gene therapies is focusing the industry on enhancing production capabilities, transitioning from ...

Investing.com -- 4basebio PLC (AIM:4BB) stock surged 6.9% on Monday after announcing that a global Tier 1 pharmaceutical partner has begun dosing patients in Phase I/II clinical trials using the ...

Cambridge, UK, 27 October 2025 - 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products announces that, following Investigational New Drug (IND) approval from the FDA, a ...

Monday that a global tier-one pharmaceutical partner had started dosing patients in a phase one and two US clinical trial ...